Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
Frontotemporal dementia
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "Frontotemporal dementia" in MCE Product Catalog:
6
6 Publications Verification
Target:
Research Areas:
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
2
2 Cited Publications
Target:
Research Areas:
ZXH-4-130 TFA is a potent and selective Cereblon (CRBN) degrader. ZXH-4-130 TFA recruits the VHL E3 ligase to specifically target CRBN as a substrate for selective degradation as a hetero-PROTAC molecule. ZXH-4-130 TFA can be applied in studies on the biological functions of CRBN and related research of frontotemporal dementia .
2
2 Cited Publications
Cat. No.: HY-132857
CAS No.: 2711006-66-3
Target:
Research Areas:
ZXH-4-130 is a potent and selective Cereblon (CRBN) degrader. ZXH-4-130 recruits the VHL E3 ligase to specifically target CRBN as a substrate for selective degradation as a hetero-PROTAC molecule. ZXH-4-130 can be applied in studies on the biological functions of CRBN and related research of frontotemporal dementia .
1
Target:
Research Areas:
Research Areas:
QC-01-175 is a Tau PROTAC degrader, with Kd values of 1.2 μM, 1.7 μM and 2.5 μM for wild-type, A152T mutant and P301L mutant tau-441 proteins, respectively. QC-01-175 binds to both Tau and CRBN, triggering ubiquitination and proteasomal degradation of Tau. QC-01-175 preferentially targets disease-associated Tau proteins in frontotemporal dementia. QC-01-175 inhibits MAO activity, with an IC50 of 8.56 μM. QC-01-175 suppresses the elevation of ROS levels. QC-01-175 can be used in studies related to frontotemporal dementia and amyotrophic lateral sclerosis .
Cat. No.: HY-NP0204
Synonyms: Mouse Serum Albumin
Target:
Research Areas:
BPN-15477 is an orally active, blood-brain barrier-permeable splicing modulator compound (SMC). BPN-15477 restores the correct splicing of exon 20 of the elongator complex protein 1 (ELP1) (EC50 = 1.9 μM), thereby significantly increasing the in vivo functional protein levels in all tissues including the brain. BPN-15477 can be used in the research of familial dysautonomia, such as frontotemporal dementia .
Target:
Research Areas:
PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with Kis of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) .
Cat. No.: HY-141878
CAS No.: 2767983-76-4
Target:
Research Areas:
di-Ellipticine-RIBOTAC is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2) exp). di-Ellipticine-RIBOTAC selectively binds the three-dimensional (3D) structure formed by r(G4C2) exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2) exp. di-Ellipticine-RIBOTAC selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2) exp. di-Ellipticine-RIBOTAC significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) .
Research Areas:
Glutamate dehydrogenase (NADP) is the catalytic enzyme for glutamate production. Dysfunction of Glutamate dehydrogenase (NADP) may induce various neurodegenerative diseases, such as Parkinson's disease, epilepsy, Alzheimer's disease, schizophrenia, and frontotemporal dementia. Glutamate dehydrogenase (NADP) can be used in research on neurological diseases such as Parkinson's disease, epilepsy, and Alzheimer's disease .
Cat. No.: HY-W141374
CAS No.: 108883-90-5
Target:
Research Areas:
CB096 is an r(G4C2) exp RNA binder with EC50 values of 19 μM, 20 μM and 33 μM. CB096 selectively interacts with the 5′CGG/3′GGC 1×1 GG internal loop motif of folded r(G4C2) exp RNA, alters motif dynamics and closed base pairs, and rescues disease-related pathways. CB096 can be used for research on inherited amyotrophic lateral sclerosis/frontotemporal dementia (c9ALS/FTD) .
Cat. No.: HY-141878A
CAS No.: 2767983-77-5
Target:
Research Areas:
di-Ellipticine-RIBOTAC TFA is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2) exp). di-Ellipticine-RIBOTAC TFA selectively binds the three-dimensional (3D) structure formed by r(G4C2) exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2) exp. di-Ellipticine-RIBOTAC TFA selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2) exp. di-Ellipticine-RIBOTAC TFA significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC TFA can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) .
Cat. No.: HY-P11092
Target:
Research Areas:
Cat. No.: HY-168007
Target:
Research Areas:
NSC804515 is an inhibitor of wild-type and R155H mutant p97/VCP ATPase, with an IC50 of about 15 nM for both targets. NSC804515 acts as an antiproliferative agent, disrupts the function of the ubiquitin-proteasome system, induces UbG76V-GFP accumulation, and shows reduced inhibitory potency against p97 variants carrying P510S, K512N, N616F and F618S mutations. NSC804515 can be used in research related to cancer, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia, as well as familial amyotrophic lateral sclerosis .
Cat. No.: HY-172902
CAS No.: 3105281-39-5
Target:
Research Areas:
RNA binder 1 (Compound 4b) is a blood-brain permeable RNA binder. RNA binder 1 can selectively bind to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. RNA binder 1 significantly reduces the levels of toxic polypeptides poly(GA) and poly(GP) produced by the G4C2 repeat sequence in amyotrophic lateral sclerosis (ALS) patient-derived cells. RNA binder 1 has no significant effect on the antisense polypeptide poly(PR), showing selectivity for sense RNA. RNA binder 1 can be used in the study of ALS and frontotemporal dementia (FTD) .
Cat. No.: HY-P992057
Target:
Research Areas:
Cat. No.: HY-189713
CAS No.: 2650573-17-2
Target:
Research Areas:
PTC-553 is a microtubule-associated protein tau (MAPT) mRNA splicing modulator. PTC-553 promotes exon 10 exclusion by modulating MAPT pre-mRNA splicing, corrects the 4R/3R tau isoform imbalance, thereby reducing the pathological accumulation of 4R tau protein and alleviating neurotoxicity. PTC-553 can be used for research on frontotemporal dementia and tauopathies .
Cat. No.: HY-189714
CAS No.: 3025238-38-1
Target:
Research Areas:
PTC-775 is a MAPT pre-mRNA splicing modulator. PTC-775 promotes MAPT exon exclusion, reduces longer tau isoforms and increases shorter isoforms. PTC-775 reduces the accumulation of total tau and hyperphosphorylated tau species (including oligomeric and insoluble forms). PTC-775 protects neurons from glutamate-induced death. PTC-775 can be used for research on frontotemporal dementia .
Cat. No.: HY-182794
CAS No.: 3056637-93-2
Research Areas:
NLRP3-IN-89 is a NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. NLRP3-IN-89 inhibits the NLRP3 inflammasome pathway, reduces IL-1β secretion, and exhibits minimal interference with the NF-κB pathway. NLRP3-IN-89 can be used for the research of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury .
Target:
Research Areas:
NCI-65828 (N-65828) sodium is a cell-permeable small molecule inhibitor. NCI-65828 inhibits the ribonuclease activity of human angiogenin and zebrafish Rnasel-1/3, as well as the activity of Mycobacterium tuberculosis AccD5 and its holoenzyme complex. NCI-65828 induces neuronal developmental defects, impairs vascular development, inhibits neurite outgrowth, and reduces protein synthesis in stem cells and neural progenitor cells, but shows no significant growth inhibitory effect on various human tumor cell lines. NCI-65828 is primarily used to study the role of angiogenin-like ribonucleases in neural and vascular development, to establish effect models of ALS-related angiogenin mutants, and in research related to amyotrophic lateral sclerosis, frontotemporal dementia, and tuberculosis .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
